Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial

[1]  G. Lyon,et al.  Cytomegalovirus Prostatitis in a Heart Transplant Recipient , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  M. Brabec,et al.  Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study , 2011, BMC Cancer.

[3]  S. Sutcliffe.  Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. , 2010, Future oncology.

[4]  J. Beuten,et al.  ' s response to reviews Title : Identification of viral infections in the prostate and evaluation of their association with cancer , 2010 .

[5]  R. Hayes,et al.  Sexually Transmissible Infections and Prostate Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.

[6]  I. Thompson,et al.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[7]  W. Isaacs,et al.  A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms , 2008, The Prostate.

[8]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[9]  H. Grönberg,et al.  No link between viral findings in the prostate and subsequent cancer development , 2006, British Journal of Cancer.

[10]  W. Flanders,et al.  Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  V. Beral,et al.  Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: A case control study , 2006, Infectious Agents and Cancer.

[12]  P. Doyle,et al.  Results from a Case-Control Study of Risk Factors for Congenital Heart Defects in Saudi Arabian Infants , 2006 .

[13]  S. Cole,et al.  Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. , 2006, The Journal of urology.

[14]  M. Leinonen,et al.  Prevalence and persistence of antibodies to herpes viruses, Chlamydia pneumoniae and Helicobacter pylori in Alaskan Eskimos: the GOCADAN Study. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  J. Crowley,et al.  Implementation of the Prostate Cancer Prevention Trial (PCPT). , 2004, Controlled clinical trials.

[16]  C. Cobbs,et al.  High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. , 2003, The Journal of urology.

[17]  P. Griffiths,et al.  Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. , 1999, The Journal of infectious diseases.

[18]  J. Mandel,et al.  Sexual factors and prostatic cancer: results from a case-control study. , 1987, Journal of gerontology.

[19]  E. Huang,et al.  Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. , 1983, Journal of the National Cancer Institute.

[20]  F. Rapp,et al.  Immune response of prostatic cancer patients to cytomegalovirus‐infected and ‐transformed human cells , 1978, Cancer.

[21]  F. Rapp,et al.  Evidence for the association of cytomegalovirus with carcinoma of the prostate. , 1977, The Journal of urology.

[22]  F. Rapp,et al.  Cytomegalovirus and cancer of the prostate: in vitro transformation of human cells. , 1977, Cancer treatment reports.